<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3480</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3480</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕГИСТРЫ И ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>STUDIES AND REGISTERS</subject></subj-group></article-categories><title-group><article-title>Амбулаторный мобильный мониторинг электрокардиограммы у пациентов с болезнью Фабри: дизайн исследования и характеристика когорты</article-title><trans-title-group xml:lang="en"><trans-title>Ambulatory electrocardiographic monitoring in patients with Fabry disease: study design and cohort characterization</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5263-5409</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котельникова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotelnikova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Владимировна Котельникова — кандидат медицинских наук, заведующий отделом профилактической кардиологии и реабилитации НИИ кардиологии.</p><p>Саратов</p></bio><bio xml:lang="en"><p>Saratov</p></bio><email xlink:type="simple">kotel_elena@mai1.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0496-4504</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сенчихин</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Senchikhin</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валерий Николаевич Сенчихин — кандидат медицинских наук, старший научный сотрудник отдела профилактической кардиологии и реабилитации НИИ кардиологии.</p><p>Саратов</p></bio><bio xml:lang="en"><p>Saratov</p></bio><email xlink:type="simple">kotel_elena@mai1.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7755-1834</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Липчанская</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Lipchanskaya</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Павловна Липчанская — кандидат медицинских наук, научный сотрудник отдела профилактической кардиологии и реабилитации НИИ кардиологии.</p><p>Саратов</p></bio><bio xml:lang="en"><p>Saratov</p></bio><email xlink:type="simple">kotel_elena@mai1.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Саратовский государственный медицинский университет им. В.И. Разумовского Минздрава России</institution></aff><aff xml:lang="en"><institution>V.I. Razumovsky Saratov State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>01</month><year>2023</year></pub-date><volume>21</volume><issue>12</issue><fpage>3480</fpage><lpage>3480</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Котельникова Е.В., Сенчихин В.Н., Липчанская Т.П., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Котельникова Е.В., Сенчихин В.Н., Липчанская Т.П.</copyright-holder><copyright-holder xml:lang="en">Kotelnikova E.V., Senchikhin V.N., Lipchanskaya T.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3480">https://cardiovascular.elpub.ru/jour/article/view/3480</self-uri><abstract><sec><title>Цель</title><p>Цель. Разработка дизайна исследования и анализ характеристик когорты пациентов с кардиологическими проявлениями болезни Фабри (БФ) с целью изучения возможностей телемониторинга электрокардиографии (ЭКГ) для скрининга сердечных аритмий (СА), требующих изменения терапевтической тактики.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В проспективное когортное исследование включено 11 пациентов (8 мужчин и 3 женщины) с документированной БФ, имеющих кардиологические жалобы и ЭКГ-признаки поражения сердца. Для телемониторинга ЭКГ использованы неинвазивные цифровые регистраторы событий ECG Dongle ("Нордавинд-Дубна", Россия). Первичная конечная точка: регистрация СА, требующих изменения терапевтической тактики (имплантации электрокардиостимулятора/дефибриллятора-кардиовертера/назначения антикоагулянтов). Вторичная конечная точка: динамика мониторируемых параметров для оперативной коррекции терапевтической схемы.</p></sec><sec><title>Результаты</title><p>Результаты. Когорта пациентов представлена лицами преимущественно мужского пола (73/27%; средний возраст 41±13,7 лет). На момент включения 8 (73%) пациентов получали заместительную ферментную терапию в течение 4-73 мес. Большинство пациентов являются активными интернет-пользователями, информированы о возможностях телемедицины и заинтересованы в дистанционном наблюдении. Основные жалобы были связаны с наличием перебоев в работе сердца, сердцебиения, дискомфорта в груди. Гипертрофия левого желудочка диагностирована на ЭКГ у 7-и (64%) пациентов. При эхокардиографии у 5-и пациентов выявлена симметричная гипертрофия левого желудочка, у 2-х — асимметричная гипертрофия межжелудочковой перегородки. Другие эхокардиографические аномалии включали поражение клапанного аппарата сердца (пролапс митрального и трикуспидального клапанов с митральной и трикуспидальной регургитацией, наличие дополнительных хорд) и расширение корня аорты. Исходно на ЭКГ преобладал синусовый ритм (10 пациентов); у 1-го пациента документирована желудочковая тахикардия, у 4-х — одиночная и парная желудочковая экстрасистолия; наджелудочковая тахикардия и экстрасистолия у 2-х пациентов. У 4-х пациентов имелось укорочение интервала PR без признаков дополнительных путей, у 1-го пациента — синдром Вольфа-ПаркинсонаУайта, 1 пациент имел удлиненный интервал QTc.</p></sec><sec><title>Заключение</title><p>Заключение. Для эффективного управления БФ требуются дополнительные мультицентровые исследования, посвященные разработке алгоритмов принятия тактических решений в процессе кардиологического мониторинга, учитывающего особенности кардиоваскулярных проявлений данного заболевания. В статье предлагается технология телемедицинского кардиологического мониторинга, использующая ЭКГ-регистраторы событий для амбулаторного скрининга СА.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To develop study design and analyze the characteristics of a cohort of patients with cardiac manifestations of Fabry disease (FD) in order to study the possibilities of electrocardiography (ECG) telemonitoring for screening for cardiac arrhythmias (CA), requiring a change in therapeutic tactics.</p></sec><sec><title>Material and methods</title><p>Material and methods. This prospective cohort study included 11 patients (8 men and 3 women) with documented FD, with cardiac complaints and ECG signs of heart involvement. For ECG telemonitoring, non-invasive digital event recorders ECG Dongle (Nordavind-Dubna, Russia) were used. Primary endpoint was registration of CA requiring a change in therapeutic tactics (implantation of a pacemaker/defibrillator-cardioverter/prescribing anticoagulants). Secondary endpoint was dynamics of monitored parameters for operational correction of the therapeutic regimen.</p></sec><sec><title>Results</title><p>Results. The cohort of patients is predominantly male (73/27%; mean age, 41±13,7 years). At the time of inclusion, 8 (73%) patients received enzyme replacement therapy for 4-73 months. Most patients are active Internet users, are aware of telemedicine possibilities and are interested in remote monitoring. The main complaints were related to cardiac function interruptions, palpitations, and chest discomfort. Left ventricular hypertrophy was diagnosed on ECG in 7 (64%) patients. Echocardiography revealed symmetrical left ventricular hypertrophy in 5 patients, asymmetric interventricular septal hypertrophy in 2 patients. Other echocardiographic abnormalities included valvular heart disease (mitral and tricuspid valve prolapse with mitral and tricuspid regurgitation, presence of supplemental chords) and aortic root dilatation. Initially, the ECG was dominated by sinus rhythm (n=10); 1 patient had documented ventricular tachycardia, 4 patients had single and coupled ventricular premature contractions; supraventricular tachycardia and premature contractions in 2 patients. Four patients had a PR interval shortening without signs of accessory pathways, 1 patient — Wolff-Parkinson-White syndrome, 1 patient — prolonged QTc interval.</p></sec><sec><title>Conclusion</title><p>Conclusion. For effective management of FD, additional multicenter studies are required to develop algorithms for making tactical decisions in the process of cardiac monitoring, taking into account the characteristics of the cardiovascular manifestations of this disease. The article proposes a technology for telemedicine cardiac monitoring using ECG event recorders for outpatient CA screening.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Фабри</kwd><kwd>сердечные аритмии</kwd><kwd>кардиологический мониторинг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Fabry disease</kwd><kwd>cardiac arrhythmias</kwd><kwd>cardiac monitoring</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполняется в рамках Государственного задания № 056-00065-22-00 "Разработка методов и алгоритмов интеллектуального анализа медицинских данных для телемедицинской модели кардиоваскулярной профилактики и реабилитации"</funding-statement><funding-statement xml:lang="en">The study is carried out within the State Assignment № 056-00065-22-00 "Development of methods and algorithms for the intellectual analysis of medical data for the telemedicine model of cardiovascular prevention and rehabilitation"</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102-11. doi:10.1093/ndt/gfp031.</mixed-citation><mixed-citation xml:lang="en">Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102-11. doi:10.1093/ndt/gfp031.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Baig S, Vijapurapu R, Alharbi F, et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM-Int J Med. 2019;112(1):3-9. doi:10.1093/qjmed/hcy120.</mixed-citation><mixed-citation xml:lang="en">Baig S, Vijapurapu R, Alharbi F, et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM-Int J Med. 2019;112(1):3-9. doi:10.1093/qjmed/hcy120.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367-73. doi:10.1016/j.ijcard.2008.03.007.</mixed-citation><mixed-citation xml:lang="en">Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367-73. doi:10.1016/j.ijcard.2008.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев А. С., Мершина Е. А., Сафарова А. Ф. и др. Поражение сердца при болезни Фабри: особенности течения и диагностическое значение магнитно-резонансной томографии и speckle-tracking эхокардиографии. Клиническая фармакология и терапия. 2022;31(3):14-21. doi:10.32756/0869-5490-2022-3-22-29.</mixed-citation><mixed-citation xml:lang="en">Moiseev AS, Mershina EA, Safarova AF, et al. Heart involvement in Fabry disease: clinical features, cardiac MRI and speckletracking echocardiography. Klinicheskaya farmakologiya i terapiya. 2022;31(3):14-21. (In Russ.) doi:10.32756/0869-5490-2022-3-22-29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vijapurapu R, Kozor R, Hughes DA, et al. A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. Trials. 2019;20(1):314. doi:10.1186/s13063-019-3425-1.</mixed-citation><mixed-citation xml:lang="en">Vijapurapu R, Kozor R, Hughes DA, et al. A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. Trials. 2019;20(1):314. doi:10.1186/s13063-019-3425-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802-08. doi:10.1093/eurheartj/ehs166.</mixed-citation><mixed-citation xml:lang="en">Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802-08. doi:10.1093/eurheartj/ehs166.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Acharya D, Robertson P, Kay GN, et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35(12):738-40. doi:10.1002/clc.22047.</mixed-citation><mixed-citation xml:lang="en">Acharya D, Robertson P, Kay GN, et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35(12):738-40. doi:10.1002/clc.22047.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Namdar M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Fronn Cardiovasc Med. 2016;3:7. doi:10.3389/fcvm.2016.00007.</mixed-citation><mixed-citation xml:lang="en">Namdar M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Fronn Cardiovasc Med. 2016;3:7. doi:10.3389/fcvm.2016.00007.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation. 2007;116:e350-1. doi:10.1161/CIRCULATIONAHA.107.723387.</mixed-citation><mixed-citation xml:lang="en">Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation. 2007;116:e350-1. doi:10.1161/CIRCULATIONAHA.107.723387.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Baig S, Edwards N, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018; 20(FI2):f153-61. doi:10.1093/europace/eux261.</mixed-citation><mixed-citation xml:lang="en">Baig S, Edwards N, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018; 20(FI2):f153-61. doi:10.1093/europace/eux261.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">O’Mahony C, Coats C, Cardonna M, et al. Incidence and predictors of anti-bradycardia pacing in patients with AndersonFabry disease. Europace. 2011;13(12):1781-8. doi:10.1093/europace/eur267.</mixed-citation><mixed-citation xml:lang="en">O’Mahony C, Coats C, Cardonna M, et al. Incidence and predictors of anti-bradycardia pacing in patients with AndersonFabry disease. Europace. 2011;13(12):1781-8. doi:10.1093/europace/eur267.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Namdar M, Kampmann C, Steffel J, et al. PQ interval in patients with Fabry disease. Am J Cardiol. 2010;105(5):753-6. doi:10.1016/j.amjcard.2009.10.056.</mixed-citation><mixed-citation xml:lang="en">Namdar M, Kampmann C, Steffel J, et al. PQ interval in patients with Fabry disease. Am J Cardiol. 2010;105(5):753-6. doi:10.1016/j.amjcard.2009.10.056.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Motwani M, Banypersad S, Woolfson P, et al. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab. 2012;107(1-2):197-202. doi:10.1016/j.ymgme.2012.05.011.</mixed-citation><mixed-citation xml:lang="en">Motwani M, Banypersad S, Woolfson P, et al. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab. 2012;107(1-2):197-202. doi:10.1016/j.ymgme.2012.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kharlap MS, Myasnikov RP, Pavlunina TO, et al. Сardiac phenotype of Fabry disease. Russian Journal of Cardiology. 2018;(7):80-3. (In Russ.) Харлап М. С., Мясников Р. П., Павлунина Т. О. и др. Кардиологический фенотип болезни Фабри. Российский кардиологический журнал. 2018;(7):80-3. doi:10.15829/15604071-2018-7-80-83.</mixed-citation><mixed-citation xml:lang="en">Kharlap MS, Myasnikov RP, Pavlunina TO, et al. Сardiac phenotype of Fabry disease. Russian Journal of Cardiology. 2018;(7):80-3. (In Russ.) doi:10.15829/15604071-2018-7-80-83.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Weidemann F, Maier SK, Stork S, et al. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients with Advanced Fabry Cardiomyopathy. Am J Cardiol. 2016;118(2):64-74. doi:10.1016/j.amjcard.2016.04.033.</mixed-citation><mixed-citation xml:lang="en">Weidemann F, Maier SK, Stork S, et al. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients with Advanced Fabry Cardiomyopathy. Am J Cardiol. 2016;118(2):64-74. doi:10.1016/j.amjcard.2016.04.033.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Мамчур С. Е., Хоменко Е. А., Чичкова Т. Ю. и др. Неинвазивное длительное мониторирование электрокардиограммы против имплантации петлевого регистратора для оценки течения фибрилляции предсердий: пилотное исследование. Вестник аритмологии. 2018;94:5-10. doi:10.25760/VA-2018-94-5-10.</mixed-citation><mixed-citation xml:lang="en">Mamchur SE, Khomenko EA, Chichkova TYu, et al. Non-invasive long-term ECG monitoring versus loop recorder implantation for management of atrial fibrillation: a pilot study. Journal of Arrhythmology. 2018;(94):5-10. (In Russ.) doi:10.25760/VA-2018-94-5-10.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cantillon DJ, Loy M., Burkle A, et al. Association between offsite central monitoring using standardized cardiac telemetry and clinical outcomes among non-critically ill patients. JAMA. 2016;316:519-24. doi:10.1001/jama.2016.10258.</mixed-citation><mixed-citation xml:lang="en">Cantillon DJ, Loy M., Burkle A, et al. Association between offsite central monitoring using standardized cardiac telemetry and clinical outcomes among non-critically ill patients. JAMA. 2016;316:519-24. doi:10.1001/jama.2016.10258.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Marston HR, Hadley R, Banks D, et al. Mobile Self-Monitoring ECG Devices to Diagnose Arrhythmia that Coincide with Palpitations: A Scoping Review. Healthcare. 2019;7(3):96. doi:10.3390/healthcare7030096.</mixed-citation><mixed-citation xml:lang="en">Marston HR, Hadley R, Banks D, et al. Mobile Self-Monitoring ECG Devices to Diagnose Arrhythmia that Coincide with Palpitations: A Scoping Review. Healthcare. 2019;7(3):96. doi:10.3390/healthcare7030096.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Acharya D, Doppalapudi H, Tallaj JA. Arrhythmias in Fabry cardiomyopathy. Card Electrophysiol Clin. 2015;7(2):283-91. doi:10.1016/j.ccep.2015.03.014.</mixed-citation><mixed-citation xml:lang="en">Acharya D, Doppalapudi H, Tallaj JA. Arrhythmias in Fabry cardiomyopathy. Card Electrophysiol Clin. 2015;7(2):283-91. doi:10.1016/j.ccep.2015.03.014.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz A, Germain DP, Desnick RJ, et al. Monitoring Fabry disease in adult patients. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-27. doi:10.1016/j.ymgme.2018.02.014.</mixed-citation><mixed-citation xml:lang="en">Ortiz A, Germain DP, Desnick RJ, et al. Monitoring Fabry disease in adult patients. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-27. doi:10.1016/j.ymgme.2018.02.014.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51(1):50-9. doi:10.1016/j.jjcc.2007.12.001.</mixed-citation><mixed-citation xml:lang="en">Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51(1):50-9. doi:10.1016/j.jjcc.2007.12.001.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Khidirova LD, Magomedova AKh, Vasilenko AA, et al. Fabry’s disease in cardiological aspect. Medical alphabet. 2020;7:22-7. (In Russ.) Хидирова Л. Д., Магомедова А. Х., Василенко А. А. и др. Болезнь Фабри в кардиологическом аспекте. Медицинский алфавит. 2020;7:22-7. doi:10.33667/2078-5631-2020-7-22-27.</mixed-citation><mixed-citation xml:lang="en">Khidirova LD, Magomedova AKh, Vasilenko AA, et al. Fabry’s disease in cardiological aspect. Medical alphabet. 2020;7:22-7. (In Russ.) doi:10.33667/2078-5631-2020-7-22-27.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Ann Noninvasive Electrocardiol. 2017;22(3):e12447. doi:10.1111%2Fanec.12447.</mixed-citation><mixed-citation xml:lang="en">Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Ann Noninvasive Electrocardiol. 2017;22(3):e12447. doi:10.1111%2Fanec.12447.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
